arrow attorney-female attorney-male btn-close btn-menu checkmark document facebook g-plus linkedin logo play search twitter
COVID-19 - Learn More
Call 24/7 (877) 562-0000
  • Search
  • About Cory Watson
    • Our Attorneys
    • Partnership Opportunities
    • Testimonials
    • News
    • Blog
    • Cory Watson Cares
  • Cases We Handle
    • Nationwide
    • Alabama
    • Tennessee
  • Contact Us
    • Nationwide
    • Birmingham
    • Memphis
    • Nashville

Zofran Linked to Potential Birth Defects

Cory Watson AttorneysBy Cory Watson Attorneys | May 26th, 2016

Zofran (generic name: ondansetron) is a popular anti-nausea prescription drug, approved by the US Food and Drug Administration (FDA) for treatment of nausea and vomiting in cancer patients after surgery.

The drug is manufactured by GlaxoSmithKline (GSK), a large pharmaceutical company based in the United Kingdom.

While Zofran is only FDA-approved for treatment of nausea and vomiting in postoperative and cancer patients, it is also prescribed as treatment for pregnancy-associated vomiting and nausea, commonly referred to as “morning sickness.”

Birth defects caused by Zofran

Zofran and its generic form Ondansetron have been linked to birth defects caused by the drug’s non-FDA approved, or “off-label,” use to treat morning sickness in pregnant women.

An estimated 70 to 90 percent of pregnant women experience morning sickness, and about 15 percent of all pregnant women experience morning sickness severe enough to warrant medication.

Morning sickness is most common during the first trimester of pregnancy, although it can still occur later down the line.  During the first trimester, the developing fetus is at its most vulnerable to damage caused by a harmful drug.

Zofran use during pregnancy has been shown to significantly increase the risk of severe birth defects.

Potential birth defects caused by Zofran (ondansetron) include, but are not necessarily limited to:

  • Heart defects, such as atrial or ventricular septal defects (holes in the heart), and heart murmurs
  • Cleft lip and cleft palate
  • Kidney damage and/or failure
  • Organ malformation or malpositioning
  • Miscarriage and stillbirth

Off-label drugs and pregnancy

“Off label” use describes when a medication is prescribed for a condition(s) not approved by the FDA.  Most people would assume that when their doctor prescribes them a drug, that medication has been FDA-approved for the specific condition they have.

However, off-label prescriptions are actually a common practice.  About one in five prescriptions written in the United States are off-label, according to a 2006 study by researchers at Dartmouth Medical School.

Ethical considerations prevent most drugs from being tested in pregnant patients before approval.  As a result, few drugs are expressly approved for use during pregnancy, and the effects of most drugs on fetal development as well as the risk of birth defects are poorly understood.  This also means that the proportion of drugs prescribed off-label to pregnant women is particularly high.

One in four pregnant women in America prescribed Zofran or Ondansetron

In an editorial published in the December 2014 issue of the American Journal of Obstetrics and Gynecology, Dr. Gideon Koren reports:

97.7 percent of prescriptions for the treatment of nausea and vomiting [aka morning sickness] in the United States are with medications not labeled for use in pregnancy, not indicated for nausea and vomiting in pregnancy, and not classified as safe in pregnancy by the Food and Drug Administration.

Koren highlights the steady increase in ondansetron prescriptions for treatment of morning sickness from 50,000 per month in 2008 to 110,000 per month in 2013.  Assuming this trend has since held steady, this means that roughly 1 million pregnant women out of 4 million total pregnancies per year in the United States are exposed to Zofran or its generic, ondansetron.

2012 GSK settlement

In 2012, GlaxoSmithKline (GSK) pled guilty on criminal and civil charges brought against the company by the Department of Justice for failure to report safety data and unlawful promotion of a number of its drugs, including Zofran.  GSK ended up paying $3 Billion to resolve charges – the largest pharmaceutical settlement in U.S. history.

GSK promoted Zofran for non-approved use for treatment of morning sickness and also paid kickbacks to physicians for prescribing the drug.

This 2012 settlement does not clear GSK of its liability for damages or injuries that may have been caused by Zofran.

We want to help

The attorneys at Cory Watson have represented families harmed by the negligence and wrongful conduct of others for more than thirty years, and our lawyers are currently representing women and children harmed by Zofran and other drugs.

If you or a loved one were injured by Zofran or another prescription drug, call today for a free consultation at this number: 877-686-8992

Categories

  • Abilify (2)
  • Asbestos (6)
  • Car Accidents (75)
  • Class Actions (9)
  • Community (29)
  • Cory Watson Attorneys (32)
  • Dangerous Drugs (28)
  • Defective Products (63)
  • Drug Litigation (23)
  • DuPont C8 (7)
  • Environmental (22)
  • Essure Birth Control (5)
  • Firm News (7)
  • Food Poisoning (1)
  • Industry News (13)
  • Legal Guide (9)
  • Legionnaires' Disease (9)
  • Medical Malpractice (1)
  • Mesothelioma (6)
  • Personal Injuries (43)
  • Product Liability (18)
  • Sexual Assault (23)
  • Talcum Powder Cancer (11)

Subscribe to Our Blog

Loading

Contact Our 24/7 Nationwide Lawyers

  • This field is for validation purposes and should be left unchanged.
 

Memphis, TN

Cory Watson Attorneys
254 Court Avenue, Suite 511
Memphis TN, 38103, USA

Local (901) 402-2000
Nationwide (877) 562-0000

View Location

Birmingham, AL

Cory Watson Attorneys
2131 Magnolia Ave S
Birmingham, AL 35205, USA

Local (205) 328-2200
Nationwide (877) 562-0000

View Location

Nashville, TN

Cory Watson Attorneys
1033 Demonbreun St., Ste. 300
Nashville, TN 37203, USA

Local (615) 205-0000
Nationwide (877) 562-0000

View Location

Subscribe to our newsletter

  • Blog
  • Careers
  • Disclaimer
  • Privacy Policy

Alabama Rules of Professional Conduct require the following disclaimer: Case descriptions, recoveries and testimonials presented here are not an indication of future results. Every case is different and must be evaluated on its own facts and circumstances as they apply to the law. Litigation outcome and valuation depend on many factors including jurisdiction, venue, witnesses, parties, testimony and documentary evidence. Furthermore, no representation is made that the quality of legal services to be performed is greater than the quality of legal services performed by other lawyers.

Law Firm Marketing by cj Advertising

Inquire NowRequest Free Consultation
Free Consultation Form
  • This field is for validation purposes and should be left unchanged.
fbq('track', 'PageView');